Study of two controlled-release theophylline preparations

      This paper is only available as a PDF. To read, Please Download here.


      Two sustained-release theophylline preparations, one a 12-hour and the other a 24-hour product, were compared in 20 subjects with stable asthma. All patients had good control of symptoms, and the calculated pharmacokinetic parameters were comparable for both drugs. The 24-hour sustained-release preparation can thus be utilized in the therapy of asthma.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hendeles L
        • Weinberger M
        • Wyatt R
        Guide to oral theophylline therapy in the treatment of chronic asthma.
        Am J Dis Child. 1978; 132: 876-880
        • Rail TW
        Central nervous system stimulants.
        in: Gilman AG The pharmacological basis of therapeutics. 6th ed. Macmillan, New York1980: 602-606
        • Bell T
        • Bigley J
        Sustained release theophylline therapy for chronic childhood asthma.
        Pediatrics. 1978; 62: 352-358
        • Tabachnik E
        • Scott P
        • Correia J
        • et al.
        Sustained release theophylline: a significant advance in the treatment of childhood asthma.
        J Pediatr. 1982; 100: 489-492
        • Dasta J
        • Mirtallo JM
        • Altman M
        Comparison of standard and sustained release theophylline tablets in patients with chronic obstructive pulmonary disease.
        Am J Hosp Pharm. 1979; 36: 613-617
        • Jacobs MH
        • Senior RM
        • Kessler G
        Clinical experience with theophylline.
        in: Relationship between dosage, serum concentration and toxicity. JAMA. 235. 1976: 1983-1986
        • Tinkelman DG
        • Vanderpool GE
        • Carroll MS
        • Page EG
        • Spangler DL
        Compliance differences following administration of theophylline at six and twelve hour intervals.
        Ann Allergy. 1980; 44: 283-286
        • Hendeles L
        • Weinberger M
        • Bigley L
        Absolute bioavailability of oral theophylline.
        Am J Hosp Pharm. 1977; 34: 525-527
        • Mitenko PA
        • Ogilivie RI
        Bioavailability and efficacy of a sustained release theophylline tablet.
        Clin Pharmacol Ther. 1974; 16: 720-726
      1. Horodniak J, Pav J: Personal communication.

        • Hendeles L
        • Iafrate RP
        • Weinberger M
        A clinical and pharmacokinetic basis for the selection and use of slow release theophylline products.
        Clin Pharmacokinet. 1984; 9: 95-135
      2. Biopharmaceutics and relevant pharmacokinetics. Drug Intelligence Publications, Hamilton, Illinois1984: 278-285
        • Weinberger M
        The pharmacology and therapeutic use of theophylline.
        J Allergy Clin Immunol. 1984; 73: 525-540
        • Cohen BM
        Serum profile and bioavailability of a controlled release theophylline formulation for once a day use: comparison with a 12 hr preparation.
        J Asthma. 1984; 21: 305-309